U.S. Rep. Clyburn Explains How Clinical Trials Provide Opportunity to Address Health Disparities
PhRMA: 9/10/13 As you may know from a previous Catalyst post, late last month we unveiled a new report on “Research in Your Backyard: Pharmaceutical Clinical Trials in South Carolina”. We were honored to be joined by U.S. Representative James E. Clyburn who addressed the importance of clinical trials to making new medicines available to patients, and how the […]
Clinicaltrials.gov Database Reveals “Sausage Making” in Clinical Research
JAMA: 9/10/13 With more than 150 000 clinical trials now registered, clinicaltrials.gov, the database created to increase transparency in clinical research, is providing some unflattering insights, according to research findings reported at the Seventh International Congress on Peer Review and Biomedical Publication in Chicago this week. No one anticipated the role of clinicaltrials.gov “as a window into […]
Clinical trial participation improves outcome: A matched historical cohort study
Clin Trials: September 3, 2013 Background Well-conducted, investigator-led randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy of new treatments and are a key component of evidence-based medicine. It is unclear whether participating in an RCT is beneficial to the individual before the results of RCTs are known. Purpose In a matched historical cohort study, […]
As Hispanics lag in clinical trials, health researchers take action: Outreach expands
The Nation’s Health: September 2013 There are 53 million Hispanics living in the United States today. That number is expected to grow, reaching more than 128 million by 2060, the U.S. Census Bureau predicts. Also growing is the disproportionately high number of Hispanics living with chronic conditions such as high blood pressure, diabetes and cancer. But […]
The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?
NEJM: 9/1/13 The randomized trial is one of the most powerful tools clinical researchers possess, a tool that enables them to evaluate the effectiveness of new (or established) therapies while accounting for the effects of unmeasured confounders and selection bias by indication. Randomized trials, especially huge megatrials, have transformed medical practice. Thanks to randomized trials, […]
New treatments better than standard ones just over half the time
Medicalnewstoday: 8/29/13 USF Distinguished Professor Benjamin Djulbegovic, MD, PhD, has studied the ethics of randomized clinical trials and their effectiveness in evaluating the outcomes of new treatments for decades. Now, in a paper published in the top journal Nature, Dr. Djulbegovic and colleagues report that on average new treatments work better than existing ones just over […]
Comparative Mortality Risk in Adult Patients With Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, and Attention-Deficit/Hyperactivity Disorder Participating in Psychopharmacology Clinical Trials
Importance There is concern that increased mortality risk among patients with psychiatric illness may be worsened by psychopharmacological agents. Objectives To assess mortality risk among adult patients with a diagnosis of schizophrenia, depression, bipolar disorder, anxiety disorders, or attention-deficit/hyperactivity disorder participating in clinical trials conducted by pharmaceutical companies for US Food and Drug Administration (FDA) […]
